Literature DB >> 33258528

TEN/SJS-like lupus erythematosus presentation complicated by COVID-19.

Mohammad Shahidi-Dadras1, Farnaz Araghi1, Arman Ahmadzadeh2, Azadeh Rakhshan3, Mohammadreza Tabary4, Sahar Dadkhahfar1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 33258528      PMCID: PMC7744967          DOI: 10.1111/dth.14612

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   3.858


× No keyword cloud information.
Dear Editor Toxic epidermal necrolysis (TEN) and Stevens‐Johnson syndrome (SJS) present with extensive epidermal detachment of the skin and mucous membranes as well as systemic involvement. Drug hypersensitivity is the major culprit for TEN, while mycoplasma pneumonia infection, vaccinations, acute graft‐vs‐host disease, and systemic lupus erythematosus (SLE) are among other causes. Prior studies have reported a rare primary presentation of LE as SJS/TEN, which is defined as a new clinical entity (SJS/TEN‐like lupus erythematosus). Herein, we report a challenging case of SJS/TEN‐like LE that highlights the importance of considering LE as a rare cause of SJS/TEN like syndrome. A 26‐year‐old female presented with a 2‐week history of generalized targetoid papule and purpuras and erosive lesions of mucosa. Her past medical history and drug history were insignificant. Lesions involved almost 70% of her body surface including palms and soles with positive Nikolsky sign (Figure 1).
FIGURE 1

A, Generalized targetoid and purpuric macules of variable size with central bullae formation in some lesions and B, Multiple targetoid and purpuric macules on the palms

A, Generalized targetoid and purpuric macules of variable size with central bullae formation in some lesions and B, Multiple targetoid and purpuric macules on the palms Laboratory data showed 2‐fold rise in liver enzymes level, 4 g proteinuria in 24 h‐urine analysis and elevated serum creatinine. Anti‐nuclear antibody and anti‐ds‐DNA, anti‐LA and anti‐RO antibody were strongly positive. Investigations for SARS‐CoV‐2 infection came back negative. Of note, mild ascites was detected in her abdominal cavity ultrasonography. After primary rheumatology consultation, the patient received methylprednisolone 500 mg as pulse therapy for three consecutive days. Skin biopsy was obtained from one of the target lesions which showed near total epidermal necrosis and subepidermal blister formation containing fibrinous material and necrotic cells admixed with some lymphocytes, neutrophils and a few eosinophils. Moreover, there was a mild perivascular infiltration of lymphocytes and a few eosinophils and neutrophils in the superficial dermis, which produced lichenoid interface reaction with Civatte body formation and melanin incontinence (Figure 2). The direct immunofluorescence (DIF) study showed focal 2+ granular anti‐IgM deposits along dermoepidermal junction. Considering the earlier corticosteroid pulse therapy, DIF was in favor of a partially treated lupus erythematosus (Figure 3).
FIGURE 2

A, Histopathologic examination showed a subepidermal blister with full thickness epidermal necrosis and mild perivascular dermatitis (H&E, ×40); B, Higher magnification shows mild superficial perivascular dermatitis and focal lichenoid tissue reaction (H&E, ×100)

FIGURE 3

Immunofluorescence study: focal immunoreactivity for anti‐IgM in dermoepidermal junction

A, Histopathologic examination showed a subepidermal blister with full thickness epidermal necrosis and mild perivascular dermatitis (H&E, ×40); B, Higher magnification shows mild superficial perivascular dermatitis and focal lichenoid tissue reaction (H&E, ×100) Immunofluorescence study: focal immunoreactivity for anti‐IgM in dermoepidermal junction Corticosteroid pulse therapy was then changed to 30 mg/day oral prednisolone plus 1 g/kg/day intravenous immunoglobulin infusion (IVIg) for 3 days resulting marked improvement of skin lesions over a week. Unfortunately, she presented with SARS‐CoV‐2 infection 4 days after her discharge, although repeated screenings for COVID‐19 were negative during her admission period. Despite urgent ICU admission, she died of acute respiratory distress syndrome (ARDS) 3 days later. The current case describes a patient with acute cutaneous lupus erythematosus (ACLE) with SJS/TEN‐like primary presentation. There are few points that may help to differentiate between the classic SJS/TEN and SJS/TEN‐like LE. For instance, the absence of exposure to etiologic factors for SJS/TEN and photo distributed patterns of skin lesions are in favor of SJS/TEN‐like LE. Further, the interval between the first rash to epidermal detachment in SJS/TEN‐like LE seems to be longer (weeks to months) than the classic SJS/TEN (hours to days). SJS/TEN‐like LE skin lesions may appear on palms and soles more frequently than SJS/TEN . Moreover, lupus specific lesions, which is characterized by interface dermatitis response, could turn the diagnosis toward SJS/TEN‐like LE. Presence of continuous IgM, IgG, and C3 deposition at basement membrane zone may be observed in DIF and is of great value in distinguishing these two entities as well. Previous reports indicated that the high level of lupus antibody profile (anti‐nuclear antibody, anti‐ds‐DNA, anti‐RO, and anti‐LA) are detected in SJS/TEN‐like LE. Involvement of internal organs in the setting of SLE that often need immunosuppressive treatment increases susceptibility to severe forms of COVID‐19; this should be taken into account before initiation of treatment in these patients. Although there is no meticulous guidelines for treating SJS/TEN‐like LE, IVIg has been reported as an efficient treatment in the literature. The possible explanation for such efficiency could be explained by the fact that IVIg blocks Fas‐Fas ligands which has a crucial role in apoptosis in both LE and SJS/TEN. On the other hand, IVIg may be considered as a safe option for those who are suffering from comorbidities and have higher risk of developing severe infection in the current pandemic. , It is noteworthy that many unusual skin presentations can occur in the setting of COVID‐19 ; however, we ruled out this condition by conducting repeated screening test for COVID‐19 during her admission period.

CONFLICT OF INTEREST

The authors certify that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

AUTHOR CONTRIBUTIONS

Mohammad Shahidi‐Dadras: Editing draft, Investigation, Conceptualization. Farnaz Araghi: Writing draft. Arman Ahmadzadeh: Data acquisition. Azadeh Rakhshan: Data acquisition. Mohammadreza Tabary: Editing draft, Visualization. Sahar Dadkhahfar: Editing draft, Supervision.
  9 in total

1.  COVID-19: the new challenge for rheumatologists. First update.

Authors:  Francesco Ferro; Elena Elefante; Ilaria Puxeddu; Chiara Baldini; Elena Bartoloni; Claudia Baratè; Sara Galimberti; Rosaria Talarico; Marta Mosca; Stefano Bombardieri
Journal:  Clin Exp Rheumatol       Date:  2020-05-26       Impact factor: 4.473

2.  Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  M Caproni; D Torchia; E Schincaglia; W Volpi; A Frezzolini; D Schena; A Marzano; P Quaglino; C De Simone; A Parodi; E Barletta; P Fabbri
Journal:  Br J Dermatol       Date:  2006-10       Impact factor: 9.302

3.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Like Lupus Erythematosus.

Authors:  Jutamas Tankunakorn; Sirima Sawatwarakul; Vasanop Vachiramon; Kumutnart Chanprapaph
Journal:  J Clin Rheumatol       Date:  2019-08       Impact factor: 3.517

4.  Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?

Authors:  Rochelle Mandelcorn; Neil H Shear
Journal:  J Am Acad Dermatol       Date:  2003-04       Impact factor: 11.527

5.  Systemic lupus erythematosus presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: a report of three cases.

Authors:  H Y Lee; H L Tey; S M Pang; T Thirumoorthy
Journal:  Lupus       Date:  2010-12-10       Impact factor: 2.911

6.  Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.

Authors:  Alexis Mathian; Matthieu Mahevas; Julien Rohmer; Mathilde Roumier; Fleur Cohen-Aubart; Blanca Amador-Borrero; Audrey Barrelet; Cecile Chauvet; Thibaud Chazal; Michel Delahousse; Mathilde Devaux; Romain Euvrard; Jehane Fadlallah; Nans Florens; Julien Haroche; Miguel Hié; Laurent Juillard; Raphael Lhote; Thibault Maillet; Gaelle Richard-Colmant; Jean Baptiste Palluy; Micheline Pha; Laurent Perard; Philippe Remy; Etienne Rivière; Damien Sène; Pascal Sève; Capucine Morélot-Panzini; Jean-François Viallard; Jean-Simon Virot; Neila Benameur; Noël Zahr; Hans Yssel; Bertrand Godeau; Zahir Amoura
Journal:  Ann Rheum Dis       Date:  2020-04-24       Impact factor: 27.973

Review 7.  Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review.

Authors:  Niloufar Najar Nobari; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-07-07       Impact factor: 3.858

8.  Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review.

Authors:  Farnoosh Seirafianpour; Sogand Sodagar; Arash Pour Mohammad; Parsa Panahi; Samaneh Mozafarpoor; Simin Almasi; Azadeh Goodarzi
Journal:  Dermatol Ther       Date:  2020-08-06       Impact factor: 3.858

9.  Blisters and Loss of Epidermis in Patients With Lupus Erythematosus: A Clinicopathological Study of 22 Patients.

Authors:  Carine Merklen-Djafri; Didier Bessis; Camille Frances; Nicolas Poulalhon; Sébastien Debarbieux; Nadège Cordel; Dan Lipsker
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  9 in total
  1 in total

1.  Toxic Epidermal Necrolysis-Like Lupus Erythematous Presentation Following SARS-CoV-2 Infection.

Authors:  Ana Luisa Nunes; Leonor Simoes; Carolina Figueiredo; Ruben Carvalho; Jandira Lima; Rui M Santos
Journal:  J Med Cases       Date:  2022-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.